News About: Pharm. Affairs
‘Azilect,’ Parkinson’s disease treatment, lands in Big 5 hospitals
A treatment, which was newly launched in 10 years in the Parkinson’s disease treatment market, has been safely settled in the ‘Big 5’ hospitals.
According to the healthcare industry on the 15th, ‘Azilect(generic name...
Korea Pharmaceutical Association President Chan-hwi Cho reelected
Chan-hwi Cho, President of Korean Pharmaceutical Association, got reelected.
President Chan-hwi Cho was elected for the next president as getting 54.9% of valid votes, 9,525 of the total 18,094 votes, in the 38th Kor...
Co-marketed products experience frequent out-of-stocks, enraging pharmacies and wholesalers
Recently, products co-marketed by domestic and foreign pharmaceutical companies have been suffered from frequent out-of-stocks.
According to the pharmacy and pharmaceutical distribution fields on the 11th, ETC drugs,...
U.S. and Japanese ‘No. 1 ‘ painkillers fail in the domestic market
Global top painkiller brand, Advil; Japanese No. 1 painkiller brand, Bufferin.
Pfizer’s’ Advil,’ a painkiller sold in 50 different countries across the world, is a super-gigantic product recording more than USD 1 bil...
10th anniversary of Zydena, erectile dysfunction treatment
Dong-A ST(President and CEO Soo-hyung Kang) held a symposium to celebrate the 10th anniversary of the ‘Zydena’ commercialization, a erectile dysfunction treatment, by inviting 120 urologists at Samcheonggak in Seongbu...
“It is inappropriate to display ‘atopy or atopic’ in cosmetics advertising”
When it came to the usage of the term, ‘atopy,’ in cosmetics wrapping papers and advertisements, the health care industry have expressed concerns.
The Ministry of Food and Drug Safety has recently given an administra...
Accelerated growth of blood glucose monitoring devices
Growth of blood glucose monitoring devices is forecasted to continue.
The Medical Device Industry Support Group of the Korea Health Industry Development Institute(KHIDI) announced demands for blood glucose monitoring...
Emergence of blockbuster-level obesity drug, but Furing and Xenical decrease narrowly
It was the year that the market has shown enormous interests on newly-launched obesity treatments after a long time.
Belviq, which acquired FDA’s approval in 13 years, has suddenly became a leading product as introdu...
Firm patent wall of ‘Nexavar,’ a liver cancer treatment, to overcome for domestic companies
The challenges of domestic pharmaceutical companies to nullify the period extension of the substance patent of ‘Nexavar(sorafenib tosilate, Bayer),’ a liver cancer targeted treatment, have encountered difficulties.
A...
Once-weekly antidiabetic agonist is launched, what is its marketability in Korea?
Since Trulicity, a Lilly’s once-weekly antidiabetic agent, a GLP-1 receptor agonist, acquired product approval, the industry has turned attention from daily treatments to weekly treatments.
Particularly, as Hanmi Pha...
